期刊
ONCOGENE
卷 28, 期 29, 页码 2621-2633出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.129
关键词
adiponectin; LKB1; invasion; migration; breast cancer
资金
- NCI NIH HHS [R01 CA131294, 5P01CA116676-030002, R01CA131294] Funding Source: Medline
- NIDDK NIH HHS [R03 DK089130-02, K01 DK077137, R03 DK089130, K01 DK077137-01A1, K01 DK076742, K01DK076742, K01 DK077137-04, K01 DK077137-05, R03 DK089130-03, K01 DK077137-02] Funding Source: Medline
Adiponectin is widely known as an adipocytokine with therapeutic potential for its markedly protective function in the pathogenesis of obesity-related disorders, metabolic syndrome, systemic insulin resistance, cardiovascular disease and more recently carcinogenesis. In the present study, we show that adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Further analysis of the underlying molecular mechanisms revealed that adiponectin treatment increased AMP-activated protein kinase (AMPK) phosphorylation and activity as evident by increased phosphorylation of downstream target of AMPK, acetyl-coenzyme A carboxylase and inhibition of p70S6 kinase (S6K). Intriguingly, we discovered that adiponectin treatment increases the expression of tumor suppressor gene LKB1 in breast cancer cells. Overexpression of LKB1 in breast cancer cells further increased adiponectin-mediated phosphorylation of AMPK. Using isogenic LKB1 knockdown cell line pair, we found that LKB1 is required for adiponectin-mediated modulation of AMPK -S6K axis and more importantly, inhibition of adhesion, migration and invasion of breast cancer cells. Taken together these data present a novel mechanism involving specific upregulation of tumor suppressor gene LKB1 by which adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Our findings indicate the possibility of using adiponectin analogues to inhibit invasion and migration of breast cancer cells. Oncogene (2009) 28, 2621 -2633; doi: 10.1038/onc.2009.129; published online 1 June 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据